Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C9H12FN |
| Molecular Weight | 153.1967 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(N)CC1=C(F)C=CC=C1
InChI
InChIKey=GDSXNLDTQFFIEU-UHFFFAOYSA-N
InChI=1S/C9H12FN/c1-7(11)6-8-4-2-3-5-9(8)10/h2-5,7H,6,11H2,1H3
| Molecular Formula | C9H12FN |
| Molecular Weight | 153.1967 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:37:10 GMT 2025
by
admin
on
Mon Mar 31 23:37:10 GMT 2025
|
| Record UNII |
V8Q7K3989D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-2-FA
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1716-60-5
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY | |||
|
2-FLUOROAMPHETAMINE
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY | 2-Fluoroamphetamine (2-FA) is a stimulant drug from the amphetamine family which has been sold as a designer drug. 2-Fluoroamphetamine differs from 3- and 4-fluoroamphetamine in the position of the fluorine atom on the aromatic ring, making them positional isomers of one another. The replacement of a hydrogen atom with a fluorine atom in certain compounds to facilitate passage through the blood?brain barrier, as is desirable in central nervous system pharmaceutical agents, is a common practice due to the corresponding increase in lipophilicity granted by the substitute. | ||
|
300000028188
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY | |||
|
121531
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY | |||
|
V8Q7K3989D
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY | |||
|
DTXSID30938009
Created by
admin on Mon Mar 31 23:37:10 GMT 2025 , Edited by admin on Mon Mar 31 23:37:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
